Your session is about to expire
← Back to Search
Coagulation Factor
Wilate for Von Willebrand Disease
Phase 3
Waitlist Available
Research Sponsored by Octapharma
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Type 3 (at least four patients), severe type 2 (except 2N) or severe type 1 VWD (any of which with VWF:RCo <20%) according to medical history, requiring substitution therapy with a VWF-containing product
Minimum body weight 12.5 kg at the time of screening
Must not have
Patients receiving, or scheduled to receive, immunosuppressant drugs (other than antiretroviral chemotherapy), such as prednisone (equivalent to >10 mg/day), or similar drugs
Medical history of a thromboembolic event
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 12 months of treatment
Awards & highlights
Pivotal Trial
No Placebo-Only Group
Summary
This trial is testing a new medication to see if it is safe and effective in treating von Willebrand Disease in children under the age of 6.
Who is the study for?
This trial is for children under 6 with severe Von Willebrand Disease (VWF:RCo <20%) and a minimum body weight of 12.5 kg. They must not have had thromboembolic events, other bleeding disorders, or be on immunosuppressants like high-dose prednisone. Children can't join if they've used certain drugs recently or are allergic to the study drug's components.
What is being tested?
The trial tests 'wilate' in young patients with severe VWD as routine prevention over one year. It aims to assess how effective it is, how the body processes it, whether it causes immune reactions, and its safety profile.
What are the potential side effects?
While specific side effects for wilate aren't listed here, treatments for VWD typically may include reactions at injection sites, headaches, dizziness, allergic reactions or rashes. Close monitoring will identify any potential side effects during the trial.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have a severe type of Von Willebrand Disease and need treatment with a specific product.
Select...
I weigh at least 12.5 kg.
Select...
I am under 6 years old.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I am taking, or will take, drugs that lower my immune system, like high-dose prednisone.
Select...
I have had a blood clot in the past.
Select...
I haven't had DDAVP or VWF treatments in the last 3 days.
Select...
I have a bleeding or clotting disorder.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 12 months of treatment
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 12 months of treatment
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Secondary study objectives
Efficacy of wilate in the prevention and treatment of spontaneous and traumatic breakthrough BEs based on their rate and the proportion of spontaneous and traumatic BEs successfully treated with wilate
The overall efficacy of wilate in perioperative prophylaxis against excessive bleeding as assessed at the end of the postoperative period by the responsible treating investigator
Awards & Highlights
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: wilate treatmentExperimental Treatment1 Intervention
PK: Single dose of 80 IU/kg body weight (BW). Prophylactic treatment: 30-50 IU/kg BW administered 2-3 times per week at the recommended dose of over 12 months. Minor haemorrhage: loading dose 30-50 IU/kg BW followed by a maintenance dose of 30-40 IU/kg BW every 12-24 hours to achieve von Willebrand factor activity (VWF:Ac) and FVIII:C trough levels of \>30%. Major haemorrhage: loading dose 50-80 IU/kg BW followed by a maintenance dose of 30-50 IU/kg BW every 12-24 hours to achieve VWF:Ac and FVIII:C trough levels of \>50%. Minor surgery: loading dose of 40-60 IU/kg BW followed by a maintenance dose of 20-30 IU/kg BW every 12- 24 hours for up to 3 days, to achieve VWF:Ac peak levels of 50% after loading dose and trough levels \>30% during maintenance. Major surgery: loading dose of 60-80 IU/kg BW followed by a maintenance dose of 30-40 IU/kg BW every 12-24 hours for up to 6 days or longer, to achieve VWF:Ac peak levels of 100% after loading dose and trough levels \>50% during maintenance
Find a Location
Who is running the clinical trial?
OctapharmaLead Sponsor
85 Previous Clinical Trials
11,245 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have a severe type of Von Willebrand Disease and need treatment with a specific product.I am taking, or will take, drugs that lower my immune system, like high-dose prednisone.I have had a blood clot in the past.I haven't had DDAVP or VWF treatments in the last 3 days.I have a bleeding or clotting disorder.I weigh at least 12.5 kg.I am under 6 years old.
Research Study Groups:
This trial has the following groups:- Group 1: wilate treatment
Awards:
This trial has 2 awards, including:- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger